Early stage uterine serous carcinoma: Management updates and genomic advances

Gynecologic Oncology

Volumn 129, Issue 1, 2013, Pages 244-250

  Fader, Amanda Nickles ^a   Santin, Alessandro D ^b   Gehrig, Paola A ^c  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvant therapy; Genomics; Uterine serous carcinoma

Indexed keywords

BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN PHOSPHATASE 2; TRASTUZUMAB;

AFRICAN AMERICAN; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; ENDOMETRIUM CARCINOMA; ETHNIC DIFFERENCE; GENOMICS; HUMAN; LYMPH NODE DISSECTION; META ANALYSIS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REVIEW; SOMATIC MUTATION; SYSTEMATIC REVIEW; TUMOR RECURRENCE; TUMOR VOLUME; UBIQUITINATION;

CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; UTERINE NEOPLASMS;

EID: 84875476455     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.01.004     Document Type: Review

References (81)

1. R. Siegel, E. Ward, O. Brawly, and A. Jemal Cancer Statistics. 2012 CA Cancer J Clin 62 2012 10 29
2. C.L. Creutzberg, W.L. van Putten, P.C. Koper, M.L. Lybeert, J.J. Jobsen, and C.C. Warlam-Rodenhuis Surgery and postoperative radiotherapy versus surgery alone for patients with stage I endometrial carcinoma: multicentre randomized trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma Lancet 355 2000 1404 1411
3. A.N. Fader, R.D. Drake, D.M. O'Malley, H.E. Gibbons, W.K. Huh, and L.J. Havrilesky Platinum/taxane-based chemotherapy with or without radiotherapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma Cancer 115 2009 2119 2127
4. M.B. Thomas, A. Mariani, W.A. Cliby, G.A. Keeney, K.D. Podratz, and S.C. Dowdy Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma Gynecol Oncol 107 2007 186 189
5. L.J. Havrilesky, A.A. Secord, V. Bae-Jump, T. Ayeni, B. Calingaert, and D.L. Clarke-Pearson Outcomes in surgical stage I uterine papillary serous carcinoma Gynecol Oncol 105 2007 677 682
6. C.A. Hamilton, M.K. Cheung, K. Osann, L. Chen, N.N. Teng, and T.A. Longracre Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers Br J Cancer 94 2006 642 646
7. M.G. Kelly, D.M. O'Malley, P. Hui, J. McAlpine, H. Yu, and T.J. Rutherford Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy Gynecol Oncol 98 2005 353 359
8. L. Elit, J. Kwon, J. Bentley, K. Trim, I. Ackerman, and M. Carey Optimal management for surgical stage I serous cancer of the uterus Gynecol Oncol 92 2004 240 246
9. B.M. Slomovitz, T.M. Burke, P.J. Eifel, L.M. Ramondetta, E.G. Silva, and A. Jhingran Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases Gynecol Oncol 91 2003 463 469
10. W.B. Growdon, A.J. Rauh-Hain, A. Cordon, L.A. Garrett, J.O. Schorge, and A.K. Goodman Prognostic determinants in patients with stage I uterine papillary serous carcinoma. A 15-year multi-institutional review Int J Gynecol Oncol 22 2012 417 424
11. W.K. Huh, M. Powell, C.A. Leath III, J.M. Straughn Jr., D.E. Cohn, and M.A. Gold Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy Gynecol Oncol 91 2003 470 475
12. A.N. Fader, C. Nagel, A.E. Axtell, K.M. Zanotti, J.P. Kelley, and K.N. Moore Stage II uterine papillary serous carcinoma: carboplatin/paclitaxel chemotherapy improve recurrence and survival outcomes Gynecol Oncol 112 2009 558 562
13. C.S. Dietrich III, S.C. Modesitt, P.D. DePriest, F.R. Ueuland, J. Wilder, and M.B. Reedy The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC) Gynecol Oncol 99 2005 557 563
14. S.M. Ueda, D.S. Kapp, M.K. Cheung, J.Y. Shin, K. Osann, and A. Husain Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths Am J Obstet Gynecol 198 2 2008 e1 e6 [218]
15. F.D. Cirisano Jr., S.J. Robboy, R.K. Dodge, R.C. Bentley, H.R. Krigman, and I.S. Synan Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma Gynecol Oncol 74 3 1999 385 394
16. A. Obermair, L. Mileshkin, K. Bolz, S. Kondalsamy-Chennakesavan, R. Cheuk, and P. Vasey Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma Gynecol Oncol 120 2 2001 179 184
17. G. Sutton, J.H. Axelrod, B.N. Bundy, T. Roy, H. Homesley, and R.B. Lee Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a Phase II study of the Gynecologic Oncology Group Gynecol Oncol 100 2006 349 354
18. A.L. Fields, M.H. Einstein, A.P. Novetsky, J. Gebb, and G.L. Goldberg Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC) Gynecol Oncol 108 2008 210 216
19. M.H. Einstein, M. Frimer, D.Y. Kuo, L.L. Reimers, K. Mehta, and S. Mutyala Phase II trial of adjuvant pelvic radiation "sandwiched" between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma Gynecol Oncol 124 2012 21 25
20. D.M. Boruta, P.A. Gehrig, A.N. Fader, and A.B. Olawaiye Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review Gynecol Oncol 115 2009 142 153
21. M.G. del Carmen, M. Birrer, and J.O. Schorge Uterine papillary serous cancer: a review of the literature Gynecol Oncol 127 2012 651 661
22. K.N. Moore, and A.N. Fader Uterine papillary serous carcinoma Clin Obstet Gynecol 54 2 2011 278 291
23. A.N. Fader, D.M. Boruta, A.B. Olawaiye, and P.A. Gehrig Uterine papillary serous cancer: epidemiology, pathogenesis and management Curr Opin Obstet Gynecol 22 2012 21 29
24. M. Hendrickson, J. Ross, P. Eifel, A. Martinez, and R. Kempson Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma Am J Surg Pathol 6 2 1982 93 108
25. J.V. Bokhman Two pathogenetic types of endometrial carcinoma Gynecol Oncol 1591 1982 10 17
26. E. Ko, J. Franasiak, K. Sink, W.R. Brewster, P.A. Gehrig, and V. Bae-Jump Obesity, diabetes and race in Type I and Type II endometrial cancers. 2012 ASCO Annual Meeting, June 2012, Chicago, IL J Clin Oncol 29 Suppl.; abstr 5111 2011
27. J.A. Lachance, E.N. Everett, B. Greer, L. Mandel, E. Swisher, and H. Tamimi The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer Gynecol Oncol 101 3 2006 470 475
28. G.L. Maxwell, C. Tian, J. Risinger, C.L. Brown, G.S. Rose, and J.T. Thigpen Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study Cancer 107 9 2006 2197 2205
29. R.P. Matthews, J. Hutchinson-Colas, M. Maiman, R.G. Fruchter, E.J. Gates, and D. Gibbon Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women Gynecol Oncol 65 2 1997 206 212
30. M.E. Sherman, and S.S. Devesa Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus Cancer 98 1 2003 176 186
31. J. Farley, J.I. Risinger, G.S. Rose, and G.L. Maxwell Racial disparities in blacks with gynecologic cancers Cancer 110 2 2007 234 243
32. R.A. Soslow, J.P. Bissonnette, A. Wilton, S.E. Ferguson, K.M. Alektiar, and L.R. Duska Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences Am J Surg Pathol 31 7 2007 979 987
33. P.A. Gehrig, V.L. Bae-Jump, J.F. Boggess, P.A. Groben, W.C. Fowler Jr., and L. Van Le Association between uterine serous carcinoma and breast cancer Gynecol Oncol 94 1 2004 208 211
34. J.P. Geisler, J.I. Sorosky, H.L. Duong, T.E. Buekers, M.J. Geisler, and A.K. Sood Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma Gynecol Oncol 83 3 2001 501 503
35. J.K. Chan, M.R. Manuel, M.K. Cheung, K. Osann, A. Husain, and N.N. Teng Breast cancer followed by corpus cancer: is there a higher risk for aggressive histologic subtypes? Gynecol Oncol 102 3 2006 508 512
36. K.P. Pennington, T. Walsh, M. Lee, C. Pennil, A.P. Novetsky, and K.J. Agnew BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma Cancer 119 2 2013 332 338
37. A. Bland, B. Calingaert, A.A. Secord, P.S. Lee, F.A. Valea, and A. Berchuck Relationship between tamoxifen use and high risk endometrial cancer histologic types Gynecol Oncol 112 1 2009 Jan 150 154
38. E.T. Creasman, M.F. Kohler, and F. Odicino Prognosis of papillary serous, clear cell and grade 3 stage I carcinoma of the endometrium Gynecol Oncol 95 2004 593 596
39. G.S. Huang, J.S. Gebb, M.H. Einstein, S. Shahabi, H.P. Novetsky, and G.L. Goldberg Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors Am J Obstet Gynecol 196 3 2007 e1 e5 [243]
40. J. Wang, C. Wieslander, G. Hansen, I. Cass, S. Vasilev, and C.H. Holschneider This endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers Gynecol Oncol 101 1 2006 120 125
41. M.E. Shaznik-Wikiel, S.M. Ueda, H.E. Frasure, P.G. Rose, A. Fleury, and F.C. Grumbine Abnormal cervical cytology in the diagnosis of uterine papillary serous carcinoma: earlier detection of a poor prognostic cancer subtype? Acta Cytol 55 2011 255 260
42. A.B. Olawaiye, J.A. Rauh-Hain, M. Withian-Leitch, B. Rueda, A.K. Goodman, and M.G. del Carmen Utility of pre-operative CA-125 in the management of uterine papillary serous carcinoma Gynecol Oncol 110 2008 293 298
43. J.M. Duk, J.G. Aalder, G.J. Fleuren, and H.W. de Brujin CA-125: a useful marker in endometrial carcinoma Am J Obstet Gynecol 155 1986 1097 1102
44. M. Patsner, W.J. Mann, H. Cohen, and M. Loesch Predictive or preoperative serum CA 125 levels in clinically localized and advanced endometrial carcinoma Am J Obstet Gynecol 158 1988 399 402
45. A.K. Sood, R.E. Buller, R.A. Burger, J.D. Dawson, J.L. Sorosky, and M. Berman Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome Obstet Gynecol 90 1997 441 447
46. K.A. Moller, P.A. Gehrig, L. Van Le, A.A. Secord, and J.O. Schorge The role of optimal debulking in advanced stage serous carcinoma of the uterus Gynecol Oncol 94 2004 170 174
47. N. Bansal, T.J. Herzog, A. Brunner-Brown, S.L. Wethington, C.J. Cohen, and W.M. Burke The utility and cost effectiveness of preoperative computed tomography for patients with uterine malignancies Gynecol Oncol 111 2008 208 212
48. P. Benedetti Pancini, S. Basile, F. Maneschi, A. Alberto Lissoni, M. Signorelli, and G. Scambia Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial J Natl Cancer Inst 100 2008 1707 1716
49. The writing committee on behalf of the ASTEC study group. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomized study. Lancet 2990;373:125-36.
50. L.G. Seamon, J.M. Fowler, and D.E. Cohn Lymphadenectomy for endometrial cancer: the controversy Gynecol Oncol 117 2010 6 8
51. Y. Todo, H. Kato, M. Keneuchi, H. Watari, M. Takeda, and N. Sakuragi Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis Lancet 375 2010 1165 1172
52. S. Kumar, F. Medeiros, S.C. Dowdy, G.L. Keeney, J.N. Bakkum-Gamez, and K.C. Podratz A prospective assessment of the reliability of frozen section to direct intraoperative decision making in endometrial cancer Gynecol Oncol 127 3 2012 525 531
53. M.M. Alhilli, K.C. Podratz, S.C. Dowdy, J.N. Bakkum-Gamez, A.L. Weaver, and M.E. McGree Preoperative biopsy and intraoperative tumor diameter predict lymph node dissemination in endometrial cancer Gynecol Oncol 12 2012 s0090 s8258 [Epub]
54. B.A. Goff, D. Kato, R.A. Schmidt, M. Ek, J.A. Ferry, and H.G. Muntz Uterine papillary serous carcinoma: patterns of metastatic spread Gynecol Oncol 54 1994 264 268
55. A.N. Fader, D. Starks, P.A. Gehrig, A.A. Secord, H.E. Frasure, and D.M. O'Malley An updated clinicopathologic study of uterine papillary serous carcinoma Gynecol Oncol 115 2009 244 248
56. P.A. Gehrig, P.A. Groben, W.C. Fowler Jr., L.A. Walton, and L. Van Le Noninvasive papillary serous carcinoma of the endometrium Obstet Gynecol 97 2001 153 157
57. P.A. Gehrig, L. Van Le, and W.C. Fowler Jr. The role of omentectomy during the surgical staging of uterine serous carcinoma Int J Gynecol Cancer 13 2003 212 215
58. J.L. Walker, M.R. Peidmonte, N.M. Spirtos, S.M. Eisenkop, J.B. Schlaerth, and R.S. Mannel Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer. Gynecologic Oncology Group Study LAP2 > J Clin Oncol 27 32 2009 5331 5336
59. A.M. Kornblith, H.Q. Huang, J.L. Walker, N.M. Spirtos, J. Rotmensch, and D. Cella Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study J Clin Oncol 27 32 2009 5337 5342
60. F. Zullo, S. Palomba, T. Russon, A. Falbo, M. Constantino, and Al Tolina A prospective randomized comparison between laparoscopic and laparotomic approaches in women with early stage endometrial cancer: a focus on the quality of life Am J Obstet Gynecol 205 2005 1344 1352
61. J.L. Walker, M.R. Peidmonte, N.M. Spirtos, S.M. Eisenkop, J.B. Schlaerth, and R.S. Mannel Recurrence and survival after random assignment to laparoscopy or laparotomy for comprehensive surgical staging of uterine cancer: a Gynecologic Oncology Group study J Clin Oncol 30 7 2012 695 700
62. A.N. Fader, L.G. Seamon, P.F. Escobar, H.E. Frasure, L.A. Havrilesky, and K.M. Zanotti Minimally invasive surgery versus laparotomy in women with high grade endometrial cancer: a multi-site study performed at high volume cancer centers Gynecol Oncol 126 2012 180 185
63. H.M. Keys, J.A. Roberts, V.L. Brunetto, R.J. Zaino, N.M. Spirtos, and J.D. Bloss A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study Gynecol Oncol 92 2004 744 751
64. A. Kong, N. Johnson, H.C. Kitchener, and T.A. Lawrie Adjuvant radiotherapy for stage I endometrial cancer Cochrane Database Syst Rev 4 2012 CD003916 Apr 18
65. R.L. Giuntoli, M.A. Gerardi, A. Yemelyanova, A.C. Fleury, T.P. Diaz-Montes, and R.E. Bristow Stage I noninvasive and minimally invasive uterine serous carcinoma: comprehensive staging associated with improved survival Int J Gynecol Cancer 22 2 2012 Feb 273 279
66. D. Miller, V. Filiaci, G. Fleming, R. Mannel, D. Cohn, and T. Matsumoto Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 125 2012 771
67. A.P. Kiess, S. Damast, V. Makker, M.A. Kollmeier, G.J. Gardner, and C. Aghajanian Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer Gynecol Oncol 127 2 2012 Nov 321 325
68. NCCN Clinical Practice Guidelines in Oncology Uterine neoplasms, version 3.2012 2012 National Comprehensive Cancer Network
69. E. Kuhn, R.C. Wu, G. Wu, B. Guan, J. Zhang, and Y. Wang Genome-wide analyses of uterine serous carcinoma identify pathway aberrations involving cyclin E-Fbxw7, PI3K and p53 J Natl Cancer Inst 104 2012 1503 1513
70. M. Le Gallo, A.J. O'Hara, M.L. Rudd, M.E. Urick, N.F. Hansen, and N.J. O'Neil Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes Nat Genet 44 12 2012 1310 1315
71. Y. Yarden, and M.X. Sliwkowski Untangling the erbB signalling network Nat Rev Mol Cell Biol 2 2 2001 127 137
72. K.S. El Sahwi, P.E. Schwartz, and A.D. Santin Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer Expert Rev Anticancer Ther 12 1 2012 41 49
73. NIH Clinical Trials Evaluation of carboplatin/paclitaxel with or without trastuzumab (Herceptin) in uterine serous cancer http://clinicaltrials.gov/ct2/ show/ NCT01367002
74. I.-M. Shih, P.K. Panuganti, K.T. Kuo, T.L. Mao, E. Kuhn, and S. Jones Somatic mutations of PPP2R1A in ovarian and uterine carcinomas Am J Pathol 178 4 2011 1442 1447
75. Z. Tang, H. Shu, W. Qi, N.A. Mahmood, M.D. Mumby, and H. Yu PP2A is required for centromeric localization of Sgo1 and proper chromosome segregation Dev Cell 10 2006 575 585
76. W. Chen, J.D. Arroyo, J.C. Timmons, R. Possemato, and W.C. Hahn Cancer-associated PP2A Aalpha subunits induce functional haploinsufficiency and tumorigenicity Cancer Res 65 18 2005 8183 8192
77. P. Puustinen, M.R. Junttila, S. Vanhatupa, A.A. Sablina, M.E. Hector, and K. Teittinen PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma Cancer Res 69 7 2009 2870 2877
78. M. Welcker, and B.E. Clurman FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation Nat Rev Cancer 8 2 2008 83 93
79. C. Geisen, and T. Moroy The oncogenic activity of cyclin E is not confined to Cdk2 activation alone but relies on several other, distinct functions of the protein J Biol Chem 277 42 2002 39909 39918
80. L.C. Cantley The phosphoinositide 3-kinase pathway Science 296 2002 1655 1657
81. S. Kang, A.G. Bader, and P.K. Vogt Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic Proc Natl Acad Sci U S A 2005 802 807